Form D · Biotechnology

Reprise Biomedical, Inc.

Plymouth, MN · CIK 0001782236

Offering snapshot reported Jul 1, 2026 · SEC filing

Reported sold
$9.25M
Offering amount: $10M
Investors reported
43
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
May 14, 2026
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$4.62M$9.25MMay 21, 2026: $1,450,000.00May 21, 2026Jul 1, 2026: $9,246,100.00Jul 1, 2026

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$1,450,000 → $9,246,100
  • Reported investors4 → 43

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jul 1, 2026Amendment$9,246,100$7,796,100vs May 21, 202643SEC filing
May 21, 2026Initial$1,450,000No comparison4SEC filing
Jul 11, 2025Initial$6,356,956No comparison14SEC filing
Dec 13, 2023Amendment$7,982,500$3,432,500vs Nov 2, 202377SEC filing
Nov 2, 2023Initial$4,550,000No comparison17SEC filing
Jan 25, 2023Amendment$15,297,306$2,255,000vs Jan 3, 202364SEC filing
Jan 3, 2023Initial$13,042,306No comparison55SEC filing
Mar 31, 2021Amendment$4,995,000$2,220,000vs Nov 25, 202039SEC filing
Nov 25, 2020Initial$2,775,000No comparison36SEC filing
Jul 12, 2019Initial$12,500,000No comparison51SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0 (estimated)
Finders' fees
$0
Form D file number
021-584759

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Cedar Point Capital, LLC145116Cedar Point Capital, LLC · CRD 145116

Source: Form D, filed Jul 1, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Jeff Duncan Executive
Ronald Eibensteiner Director
Jake Isenburg Executive
Steve Jagodzinski Executive
Erwin Kelen Director
Heather Kotila Executive
Tom Kouchoukos Executive
Jerrod Krueger Executive
Phil Nalbone Director
Phillip Nalbone Director
Carrie Powers Director, Executive
Howard Root Director
Jeff Ross Director
Greg Smock Executive
Tina Walters Executive
Alan Woldt Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
17400 Medina Rd., Ste. 100
Plymouth, MN, 55447
Phone: 763-284-6780